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The serotonin-N-acetylserotonin–melatonin pathway as a
biomarker for autism spectrum disorders
C Pagan1,2,3,4,12, R Delorme3,4,5,6, J Callebert1,2, H Goubran-Botros3, F Amsellem4,5, X Drouot4,7,13, C Boudebesse4,7,8, K Le Dudal4,9,
N Ngo-Nguyen4, H Laouamri4, C Gillberg10,11, M Leboyer4,7,8, T Bourgeron3,4,6 and J-M Launay1,2,4
Elevated whole-blood serotonin and decreased plasma melatonin (a circadian synchronizer hormone that derives from serotonin)
have been reported independently in patients with autism spectrum disorders (ASDs). Here, we explored, in parallel, serotonin,
melatonin and the intermediate N-acetylserotonin (NAS) in a large cohort of patients with ASD and their relatives. We then
investigated the clinical correlates of these biochemical parameters. Whole-blood serotonin, platelet NAS and plasma melatonin
were assessed in 278 patients with ASD, their 506 first-degree relatives (129 unaffected siblings, 199 mothers and 178 fathers) and
416 sex- and age-matched controls. We confirmed the previously reported hyperserotonemia in ASD (40% (35–46%) of patients), as
well as the deficit in melatonin (51% (45–57%)), taking as a threshold the 95th or 5th percentile of the control group, respectively. In
addition, this study reveals an increase of NAS (47% (41–54%) of patients) in platelets, pointing to a disruption of the serotonin-
NAS–melatonin pathway in ASD. Biochemical impairments were also observed in the first-degree relatives of patients. A score
combining impairments of serotonin, NAS and melatonin distinguished between patients and controls with a sensitivity of 80% and
a specificity of 85%. In patients the melatonin deficit was only significantly associated with insomnia. Impairments of melatonin
synthesis in ASD may be linked with decreased 14-3-3 proteins. Although ASDs are highly heterogeneous, disruption of the
serotonin-NAS–melatonin pathway is a very frequent trait in patients and may represent a useful biomarker for a large subgroup of
individuals with ASD.
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INTRODUCTION
Autism spectrum disorders (ASDs) are complex, heterogeneous
and multifactorial disorders characterized by impaired social
communication and repetitive/stereotyped behaviors. The diag-
nosis of ASD currently relies entirely on patient clinical evaluation.1
Intensive investigations are underway to identify genetic, bio-
chemical, electrophysiological or imaging markers that could
contribute to screening and/or subgrouping diagnosis in a clinical
setting. Large-scale genetic studies have pointed out a marked
heterogeneity of ASD,2 and, at the present time, routine genetic
testing only allows the etiological diagnosis of a minority of cases,
although fast technological advances may gradually lead to
enlargement of this group. Some imaging,3,4 electrophysiological5
and eye-tracking6 studies have shown promising results as
contributors to the diagnosis or to early screening tools, but they
have not been translated into clinical practice so far.7
Among the different types of paraclinical examinations,
biological markers are readily available, as well as are time and
cost efficient. Several biological abnormalities have been reported
in individuals with ASD, including neurochemical, immunological,
endocrine or metabolic variations.8–10 Among these, elevated
whole-blood serotonin (5-hydroxytryptamine) is the most repli-
cated finding, reported in more than 25 studies.11–13 A deficit in
melatonin (which derives from serotonin) has also been described
in several studies on the basis of plasma or urine samples of
individuals with ASD.14–18
Melatonin, a neurohormone mainly synthesized in the pineal
gland during the night, is a biological signal of light/dark cycles
and is considered as a major circadian synchronizer. It also
displays antioxidant and neuroprotective properties and can
directly modulate neuronal networks.19,20 The phase and ampli-
tude of the nocturnal melatonin peak display marked interindi-
vidual variations: although a consensus threshold of 10 ng l− 1 in
human plasma is classically used to determine the time of
melatonin onset, in some individuals the nocturnal peak remains
below this threshold.21 Pharmacological doses of melatonin (from
0.5 mg) can modulate circadian rhythms;22 thus it is often used in
the treatment of sleep disorders, which are commonly reported in
patients with ASD.23–28
Conversion of serotonin into melatonin involves two sequential
enzymatic steps (Figure 1a). The intermediate metabolite, N-
acetylserotonin (NAS), displays intrinsic biological properties: it is
an agonist of the TrkB receptor and may therefore share the
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neurotrophic properties of brain-derived neurotrophic factor, the
canonical TrkB ligand.29,30
In a previous study,17 we reported alterations of peripheral
serotonin and melatonin levels in patients with ASD. In the
present research, we hypothesized that (i) the intermediate NAS
might also be altered, (ii) alterations of the serotonin-NAS–
melatonin pathway might constitute a possible biomarker for a
subgroup of individuals with ASD and that (iii) they would be
associated with specific clinical profiles. Thus, to address the issue

















Figure 1. Exploration of the serotonin-NAS–melatonin pathway in the blood. Two hundred and seventy-eight patients with ASD, their first-
degree relatives (129 unaffected siblings and 377 parents) and 416 controls were sampled in the morning. Boxes indicate medians and
quartiles. Groups were compared using the Wilcoxon two-sample test. (a) Overview of the serotonin-NAS–melatonin pathway. Serotonin is
converted into NAS (N-acetylserotonin) by AANAT (arylalkylamine N-acetyltransferase, EC: 2.3.1.87), then converted into melatonin by ASMT
(acetylserotonin N-methyltransferase, EC: 2.1.1.4). (b) Whole-blood serotonin (c) Platelet N-acetylserotonin (d) Plasma melatonin (1
nM= 232 ng l− 1). (e–g) Correlations between the three parameters in patients with ASD, tested as linear (e and f) or log-linear (g) correlations.
(h) 6-Sulfatoxymelatonin measurements in overnight urine from a subgroup of 16 patients with ASD and 10 controls. ASD, autism spectrum
disorder.
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serotonin-NAS–melatonin pathway, our study was extended to a
larger cohort of patients with ASD and their relatives, including
the assessment of NAS as well as serotonin and melatonin.
MATERIALS AND METHODS
Ethics statement
The local Institutional Review Boards approved the study. Written informed
consents were obtained after oral and written information from all adult
participants of the study and from the children’s parents when subjects
were under 18 years of age.
Subjects and clinical evaluations
Unrelated patients with ASD (n= 278), their first-degree relatives (129
unaffected siblings and 377 parents, involving 171 trios, 28 index-mother
pairs and 7 index-father pairs) and 416 sex- and age-matched controls
were recruited into the Paris Autism Research International Sib-pair (PARIS)
study at specialized centers in France. The patient characteristics and
parameters are presented in Supplementary Table 1 and Supplementary
Figure 2b. All individuals, including controls, were enrolled after a medical
and psychiatric assessment using the Diagnostic Interview for Genetic
Studies for adults and Kiddie-Schedule for Affective Disorders and
Schizophrenia (K-SADS) for children. Probands with a total score 430 at
the Social Responsiveness Scale (SRS)31 or for which a diagnosis of ASD
was suspected, underwent additional screening with the Autism Diag-
nostic Interview-Revised with a parent32 and/or the Autism Diagnostic
Observation Schedule.33 The final diagnosis of ASD was made when clinical
assessment diagnosis coincided with algorithm-suggested diagnosis of
autism on either or both of the Autism Diagnostic Interview-Revised and
the Autism Diagnostic Observation Schedule. Autistic traits were measured
using SRS in first-degree relatives of probands and in controls. Repetitive
behaviors were assessed using the RBS (Repetitive Behavior Scale) for
probands and their relatives.34 General medical history (including
neurological, gastro-enterological and other conditions) was checked
during interviews. For probands with ASD, a cognitive level was assigned
using appropriate tests (Wechsler scales or Raven’s progressive matrices for
nonverbal individuals). Intellectual disability was defined as verbal and
performance IQo70. Sleep difficulties were assessed in probands, relatives
and controls by self-report (and/or parent questionnaire for probands who
were themselves not sufficiently verbal to describe sleep behaviors) during
interviews. Standard karyotyping, fragile X testing, MRI and electroen-
cephalography were performed whenever possible. Individuals diagnosed
with medical disorders related to ASD, such as fragile X syndrome, Rett
syndrome or tuberous sclerosis, were excluded from the study.
Biochemical measurements
Individuals were asked to avoid food with a high content of tryptophan
and/or serotonin (for example, chocolate, bananas) for 2 days preceding
the blood draw. Individuals receiving exogenous melatonin or psycho-
tropic drugs were excluded from the study. Blood samples were collected
in the morning between 8:30 and 10:30 and fractioned, as previously
published.17 Whole-blood serotonin was measured by high-performance
liquid chromatography.35 Plasma melatonin was measured using a
radioimmunoassay (RK-MEL, Bühlmann, Switzerland). NAS and 14-3-3 were
determined in platelet pellets by radioenzymology36 and ELISA,37
respectively. Urine samples were collected overnight (2000–0800 hours)
from 16 adult patients with high-functioning ASD and 10 adult controls. 6-
Sulfatoxymelatonin was measured by a radioimmunological method as in
Tordjman et al.16,18
Statistical analyses
Statistical analyses and graphs were performed using JMP Pro 9 (SAS,
Toronto, ON, Canada), R-statistical software (http://www.r-project.org/) and
Stata 11.0 (StataCorp, College Station, TX, USA). Because the studied
biochemical parameters were not normally distributed, categorical and
nonparametric statistical tests were preferred. Error type I was defined as
0.05. ROC curves were analyzed and the areas under the curves compared
according to the Hanley and McNeil method.38
RESULTS
Disruption of the serotonin-NAS–melatonin pathway in patients
with ASD and their relatives
Whole-blood serotonin, plasma melatonin and platelet NAS were
assessed in individuals with ASD, their first-degree relatives and
controls (Supplementary Table 1 for groups’ characteristics). To
gain statistical power efficiency, the original serotonin and
melatonin data collected for the present study were pooled with
a smaller, independent set published in a previous report.17
Separate analysis indicated no significant differences between
these two data sets (Supplementary Figure 1).
Individuals with ASD displayed elevated whole-blood serotonin
(Figure 1b), as previously reported.8,11–13 Analyses stratified by age
(two groups: below and over 16 years old) were also performed,
because serotonemia is known to be age-dependent.13,39 On the
basis of this stratification, hyperserotonemia remained significant
for patients within the two age groups (Supplementary Figure 2a).
Taking as a threshold the 95th percentile of the control group
(830 nM for children o16 years old, 655 nM for individuals of 16
years or more), hyperserotonemia was observed in 40% of
individuals with ASD. By contrast whole-blood serotonin was
significantly elevated in ~15% of their first-degree relatives (17%
for mothers, 14% for fathers and 14% for unaffected siblings—
frequencies with 95% confidence interval and comparisons with
controls and patients with ASD are summarized in Supplementary
Table 2).
Plasma melatonin was significantly decreased in individuals
with ASD and their relatives compared with controls (Figure 1d).
Taking as a threshold the 5th percentile of the control group
(0.07 nM or 16 ng l− 1), melatonin deficit was observed in 51% of
individuals with ASD, 26% of parents with a trend for a gender
effect (31% of mothers and 21% of fathers, P= 0.08) and 25% of
unaffected siblings.
For the first time to our knowledge, the intermediate metabolite
NAS, measured in blood platelets, was found to be significantly
elevated in individuals with ASD and their relatives compared with
controls (Figure 1c). Taking as a threshold the 95th percentile of
the control group (44 nmoles/109 platelets), NAS was elevated in
47% of individuals with ASD, 19% of parents (24% of mothers and
15% of fathers, P= 0.23) and 17% of unaffected siblings.
Platelet NAS was strongly correlated with plasma melatonin in
patients with ASD (Figure 1g) and to a lesser extent in parents and
controls (Supplementary Figure 3), suggesting common factors of
deregulation. In contrast, a correlation between whole-blood
serotonin and platelet NAS or plasma melatonin was observed
neither in patients (Figures 1e and f) nor in controls
(Supplementary Figure 3), pointing toward an independence of
mechanisms leading to serotonin impairment on one hand, NAS
and melatonin alterations on the other hand.
One limitation of our study is the assessment of melatonin only
from plasma sampled in the morning, as melatonin displays
marked nyctohemeral variations with a peak occurring at night.40
Thus, we extended melatonin assessment in a subgroup of 16 ASD
patients and 10 controls by measuring 6-sulfatoxymelatonin (the
main melatonin catabolite) in overnight urine. Consistent with
previous studies,16,18 nighttime 6-sulfatoxymelatonin excretion
was significantly lower in patients than in controls, thus
confirming a melatonin deficit in ASD (Figure 1h).
Serotonin, NAS and melatonin as biomarkers of ASD
Given that increased whole-blood serotonin and platelet NAS and
decreased plasma melatonin are reported in approximately half of
the patients with ASD in our study, we tested their accuracy to
discriminate patients with ASD from controls. Figures 2a and b
show that each potential biomarker performed well with areas
under the curves 40.75. Platelet NAS was as powerful as blood
serotonin in discriminating ASD patients from controls (P= 0.33 for
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serotonin vs NAS). Plasma melatonin performed better than
serotonin (P= 0.02 for serotonin vs melatonin; Figure 2c).
Considering that alterations of serotonin, NAS and melatonin
are partially independent (Figures 1e–g), we tested whether a
combination of these parameters could improve diagnostic
performances. We designed a score taking into account serotonin,
NAS and melatonin, with the 95th or 5th percentile of the control
group as pathological thresholds (Figure 2d). Using this score, 80%
sensitivity for 85% specificity was achieved for subjects displaying
at least one abnormal parameter (score ⩾ 1), and the specificity
reached 98.7% for subjects displaying two abnormal parameters
or more (score ⩾ 2) with a 50% sensitivity; interestingly, the
performance for this score was slightly better in children than in
adults (Figure 2e).
Thus, the combination of serotonin, NAS and melatonin allows a
good discrimination between ASD patients and controls.
Clinical correlates of the disruptions of the
serotonin-NAS-melatonin pathway in ASD
We evaluated the association of serotonin, NAS and melatonin
impairment with the clinical features of patients with ASD
(Table 1). Overall, we did not observe a significant association
between biochemical alterations and the severity of autistic
symptoms or a comorbid intellectual disability. A trend was
observed for an association between high blood serotonin in
patients and lower social abilities (higher SRS score), but this trend
was not consistent with the analysis of the ‘social’ (B) item of
Autism Diagnostic Interview-Revised. Similarly, a nonsignificant
trend was observed between low melatonin and higher scores on
the repetitive behavior (D) item of Autism Diagnostic Interview-
Revised, but this trend was not consistent with the analysis of the
Repetitive Behavior Scale (RBS-R) scores. No association was
observed between biochemical impairments and autistic traits
(assessed by SRS and RBS-S) in first-degree relatives of patients
(details not shown).
NAS might display neurotrophic properties as a TrkB agonist
29,30 and early brain overgrowth was reported during infancy and
the toddler years in ASD.41,42 We then explored the associations
between biochemical impairments and abnormal head sizes:
‘normal’ NAS tended to be associated with a lower frequency of
small heads (Table 1).
Sleep abnormalities are frequently associated with ASD, and
melatonin has a major role in synchronizing circadian rhythms.
Thus, we assessed sleep difficulties in patients with ASD
(Supplementary Figure 4) and explored the associations between
alterations of serotonin, NAS and melatonin and sleep difficulties.
Patients with melatonin deficit reported sleep-onset and sleep-
maintenance insomnia significantly more frequently than patients
with normal melatonin levels (Table 1). Conversely, patients
reporting sleep abnormalities displayed significantly lower mela-
tonin levels than patients without such difficulties (Supplementary
Figure 5a). This association was not observed in first-degree
relatives of patients.
In addition to self-reporting, we assessed sleep disorders by a
Children’s Sleep Habit Questionnaire43 in a subgroup of ASD and
control children, and by actigraphy and specific sleep
questionnaires44–46 in a subgroup of high-functionning ASD and
control adults (Supplementary Figure 4). The ASD patients
displayed a high frequency of sleep disorders, including mostly
insomnia (reported by 44% of patients) and delayed sleep onset.
Children’s Sleep Habit Questionnaire analysis revealed no
associations between sleep parameters and biochemical impair-
ments in the subgroup of children with ASD (data not shown). In
contrast, according to actigraphic recordings, elevated NAS was
associated with lower diurnal motor activity (M10) and tended to






















0.784 [0.745 - 0.784]
0.812 [0.768 - 0.812]
0.841 [0.805 - 0.841]















Parameter Biological matrix Threshold Score
Serotonin Whole blood < 16 years old:  830 nM
 16 years old:  655 nM 1 point
NAS Platelets 44 nmol/109 platelets 1 point
Melatonin Plasma (morning)  0.07 nM 1 point
Total / 3 pts
Specificity Sensitivity
Whole population 0.85 0.80
<16y 0.89 0.84
>16y 0.82 0.77





(1 abnormal marker 
or more)
(2 abnormal markers 
or more)
Figure 2. Diagnostic performances of the serotonin-NAS–melatonin pathway parameters in ASD. (a) ROC curve analysis for serotonin, NAS,
melatonin and the score combining all three as diagnostic markers of ASD. (b) AUC with confidence interval for each parameter. (c)
Comparisons of AUC. (d) Design of the score combining impairments of serotonin, NAS and melatonin. The pathological thresholds were
defined as the 95th percentile (for serotonin and NAS) or the 5th percentile (for melatonin) of the control group. (e) Diagnostic performances
for ASD of the score. This score is based on n= 230 controls and 229 patients, described for the whole population and after stratification by
age category. ASD, autism spectrum disorder; AUC, area under the curve; NAS, N-acetylserotonin; ROC, receiver operating characteristic.
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maximal activity (Supplementary Figure 5). A trend for an
association between the melatonin deficit and the increased
sleep latency was also observed. These results need further
replication in larger groups. No association was observed between
biochemical impairments and other comorbid psychiatric or
somatic conditions.
Disruption of 14-3-3 proteins in platelets of patients with ASD
Melatonin synthesis involves two enzymes, AANAT and ASMT,
known to form protein complexes with 14-3-3 scaffolding
proteins.47 Interaction with 14-3-3 regulates this process by
stabilizing and activating AANAT.48 In a previous study, we
reported a decrease of ASMT activity in platelets of patients with
ASD.17 Here, 14-3-3 was measured in platelets and found
significantly decreased in patients with ASD (Figure 3). Thus,
although obtained from peripheral tissues, these results suggest
that the disruption of melatonin synthesis in patients with ASD
may be linked with impairments of protein complex formation
involving 14-3-3.
DISCUSSION
The exploration of the serotonin-NAS-melatonin pathway in our
study confirmed the hyperserotonemia8,11–13 and the melatonin
deficit14–18 in ASD that has been reported in several studies, and it
also revealed an increase of NAS in platelets, pointing towards a
global disruption of this pathway in ASD.
Consistent with previous reports on serotonin and melatonin,
impairments of the serotonin-NAS–melatonin pathway were
frequent (40 to 51%) in this cohort of patients with ASD, and
may thus be considered as possible biomarkers for a large
subgroup of patients. In line with this idea, we found that
combining the three parameters was sensitive and specific for
discrimination of probands from controls.
The specificity of the combination of these biochemical
biomarkers regarding other neurodevelopmental conditions
should be further evaluated in future studies. However, previous
reports49 and our preliminary data (Supplementary Figure 6)
indicate that patients with intellectual disability not associated
with autism (ID) or patients with attention-deficit hyperactivity
disorder (ADHD) do not display as high blood serotonin levels as
patients with ASD. To our knowledge, plasma melatonin has been
documented neither in ID nor in ADHD patients. Our preliminary
data suggest that ADHD or ID patients display a decreased level of
Table 1. Clinical correlates of impairments of serotonin, NAS and melatonin in patients with ASD
Patients with High serotonin Normal
serotonin
P High NAS Normal NAS P Low melatonin Normal
melatonin
P
ADI scores, n 43 78 64 55 60 60
B (social) median (quartiles) 23 (19–27) 24 (17–27) 0.50 23 (19–27) 25 (16–29) 0.97 23 (17–26) 23 (18–27) 0.57
C (verbal communication median
(quartiles)
16 (9–20) 15 (12–18) 0.28 16 (12–19) 15 (9–19) 0.31 16 (12–20) 14.5 (9–18) 0.33
C (nonverbal communication)
median (quartiles)
12 (6–14) 10 (7–14) 0.60 11 (8–14) 10 (5–14) 0.38 11 (8–14) 11 (5–14) 0.73
D (repetitive behavior) median
(quartiles)
6 (3–8) 6.5 (5–8) 0.12 7 (4–9) 6 (4–7) 0.38 7 (5–9) 6 (4–8) 0.07
n 32 49 40 40 47 30
RBS total score median (quartiles) 14 (8–33) 23.5 (14–34) 0.21 19 (9–34) 26 (14–34) 0.34 20 (9–32) 26 (13–38) 0.17
SRS total score median (quartiles) 91 (76–102) 79 (71–92) 0.07 82 (70–97) 85 (73–104) 0.34 83 (74–102) 83 (65–95) 0.24
n 41 77 64 52 60 57
Intellectual disability (n%) 11 (27%) 17 (22%) 0.65 15 (23%) 12 (23%) 1 13 (22%) 14 (25%) 0.83
Head circumference, n 47 80 68 56 61 65
Small (o10th percentile) (n%) 4 (9%) 4 (5%) 0.73 7 (10%) 1 (2%) 0.07 4 (7%) 4 (6%) 0.17
Large (490th percentile) (n%) 17 (36%) 30 (38%) 27 (40%) 18 (32%) 27 (44%) 19 (29%)
Insomnia (self-report), n 50 96 78 65 77 68
(n%) 18 (36%) 46 (48%) 0.22 38 (49%) 25 (38%) 0.24 40 (52%) 24 (35%) 0.05
Abbreviations: ADI-R, Autism Diagnostic Interview-Revised; ASD, autism spectrum disorder; B, social interactions; C, verbal and nonverbal communication; D,
stereotyped behavior; NAS, N-acetylserotonin; RBS, Repetitive Behavior Scale; SRS, Social Responsiveness Scale. For each biochemical parameter, patients with
ASD were classified into normal and pathological group (high or low) on the basis of the threshold of the 95th or 5th percentiles of the control group. The two
groups were compared using the Fisher’s exact test for categorical items (n and % of individuals with diagnosis are indicated) and the Wilcoxon two-sample
test for quantitative items (medians and quartiles are indicated). Because the number of individuals investigated displays mild variations across biochemical
parameters and across clinical items, the total sample size (n) is indicated separately for each test. Intellectual disability is defined as verbal IQ and performance






















Figure 3. 14-3-3 protein measurement in platelets. Forty patients
with ASD and 70 controls were assessed. Boxes indicate medians
and quartiles. Groups were compared using the Wilcoxon two-
sample test. ASD, autism spectrum disorder.
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plasma melatonin, but less pronounced than in ASD. ROC curve
analysis indicated that whole-blood serotonin and plasma
melatonin were discriminant between ADHD or ID patients and
ASD patients, but not between ADHD or ID patients and controls
(Supplementary Figure 6).
Disruption of the serotonin-NAS–melatonin pathway was also
observed in first-degree relatives of patients with ASD, suggesting
a genetic liability. This finding is consistent with previous reports
of (i) increased serotonin among parents and siblings of patients
with ASD,13,50–52 (ii) decreased melatonin among parents17 and
(iii) strong heritability of serotonin53 and melatonin54 reported in
the general population. However, in our cohort, disruption of the
serotonin-NAS–melatonin pathway does not always segregate in
the families with ASD and rarely with a simple recessive/dominant
model, suggesting a complex inheritance. Interestingly, mothers
of patients with ASD would tend to display more pronounced
biochemical impairments (elevated platelet NAS and low melato-
nin) than fathers. Considering that melatonin crosses the placental
barrier, melatonin deficit in a mother might result in insufficient
fetal exposure to melatonin in utero, and might thus be a prenatal,
environmental susceptibility factor to ASD.
The search for clinical correlates of disruptions of the serotonin-
NAS–melatonin pathway yielded no significant associations with
ASD symptom severity or presence of intellectual disability. In
addition, no association was found between biochemical impair-
ments and diagnostic categories of ASD according to the DSM-IV
(autism, Asperger syndrome, PDD-NOS—data not shown), which
suggests that a defect in the serotonin-NAS–melatonin pathway is
a shared feature across the spectrum.
Attempts to link whole-blood serotonin levels to clinical
symptoms have been inconsistent. However, the overall evidence
implicates the serotonin system in ASD: serotonin is crucial for
embryonic brain development55,56 and regulates the release of
oxytocin whose signal alterations are important for ASD57 and
which promotes social behavior in high-functioning ASD
patients.58 Of note, oxytocin and serotonin interact in the human
brain59 and their blood levels are negatively correlated in
humans.60
One study reported an association between melatonin deficit
and language difficulties in patients with ASD,16 but we were not
able to replicate this finding. In our study, we observed a
significant association between melatonin deficit and sleep
problems in patients. Sleep difficulties are frequently associated
with ASD and are a major concern for the patients and their
families.61,62 These results provide a rationale for the therapeutic
use of melatonin in sleep disorders associated with ASD.23–28,63
A possible pitfall of this study is that melatonin levels were
assessed only at one time point (over a 2-h window well after
sleep offset) and not under dim light conditions. Obviously these
conditions are not adequate for assessing the endogenous phase
or amplitude of nocturnal melatonin secretion. However, they
allow a good discrimination between patients and controls and
are more convenient in a clinical setting than nocturnal melatonin
assessment. Furthermore, nighttime 6-sulfatoxymelatonin excre-
tion in a subset of patients confirmed a nocturnal melatonin
deficit, consistent with previous studies.16,18 To the best of our
knowledge the circadian rhythm of platelet NAS has not been
reported, whereas whole-blood or platelet serotonin only displays
minor (o10%) circadian variations.64,65
We reported for the first time an increase of the intermediate
metabolite NAS in platelets of patients with ASD. Interestingly,
NAS displays proper biological functions. At a metabolic level, it is
an inhibitor of tetrahydrobiopterin synthesis,66 a cofactor of
several pathways such as nitric oxide formation67 and tyrosine/
bioamine synthesis. Thus, in addition to the possible conse-
quences of alterations of serotonin and melatonin,6,20 NAS
accumulation may have implications for the pathophysiology
of ASD.
The mechanisms of these impairments of the serotonin-NAS–
melatonin pathway in ASD remain to be elucidated. Various
studies have not succeeded in revealing a convincing mechanism
for hyperserotonemia.68 Considering that melatonin synthesis
represents only a small fraction (about 1%) of serotonin
catabolism, it is unlikely that an impairment of melatonin
synthesis would be sufficient to provoke a significant increase of
serotonin. Our previous study17 suggested that melatonin deficit
results from impaired synthesis as a consequence of a decrease in
ASMT activity. This enzymatic alteration may be associated with
genetic factors, including coding mutations in a subset of patients
with ASD—although with a low frequency—and polymorphisms
in the ASMT promoter (rs4446909 and rs5989681) with functional
effects. The association finding was not fully replicated in an
independent study, although a similar trend was observed.69
Interestingly, these SNPs have also been associated with bipolar
disorder,70 depression71 and depressive symptoms in individuals
with sleep phase delay.72 Here we show that 14-3-3 scaffolding
protein levels are decreased in patients with ASD. As protein
complex formation involving 14-3-3 regulate melatonin
synthesis,47,48 we propose that impairments of posttranslational
regulations of AANAT and/or ASMT may participate in the
mechanisms of the disruption of melatonin synthesis in ASD.
Although ASDs are considered as highly heterogeneous, this
study reports disruptions of the serotonin-NAS–melatonin path-
way as a highly sensitive and specific biomarker of ASD.
Associations with sleep problems provide a rationale for
melatonin therapy. Finally, these results open new hypotheses
for the mechanisms of impairments of melatonin synthesis in ASD.
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